Conform Pharm

Based in China, Conform Pharm develops innovative pharmaceutical products, focusing on pediatric and ophthalmic therapies that enhance patient care and treatment options. Conform Pharm is a pharmaceutical development company located in Wuhan, China, founded in 2007. The company specializes in creating therapeutic solutions, particularly for children and ophthalmic conditions. Its founder has not been specified, and there is no indication of a parent company or subsidiaries.

Conform Pharm has executed a total of 5 deals to date, with its most recent deal occurring on May 21, 2025, when it raised Series B+ funding. Wuhan Kefu New Drug Co. , Ltd. , which operates under the name Conform Pharm, focuses on developing and commercializing pharmaceutical products, with particular emphasis on pediatric and ophthalmic therapies.

Its leading product, He Meijia® (Propranolol Hydrochloride Oral Solution), is significant for treating conditions such as infantile hemangiomas in young patients. The company utilizes an advanced technical platform based on nanoformulation to enhance drug delivery methods, including oral, ocular, transdermal, and injectable applications. He Meijia® is marketed in China under an exclusive license agreement with Pierre-Fabre, allowing Kefu to develop and distribute this critical product. Conform Pharm serves a varied clientele, including healthcare facilities, pharmacies, and end consumers, with a focus on improving patient outcomes through scientifically validated formulations.

Wuhan Kefu New Drug Co. , Ltd. primarily generates revenue from the sale of its proprietary pharmaceutical products, particularly He Meijia® (Propranolol Hydrochloride Oral Solution). It employs a direct-to-consumer sales model alongside partnerships with healthcare providers and pharmacies for product distribution.

Transactions typically occur on a per-unit basis through prescriptions issued by healthcare practitioners, leading to retail purchases by patients. The company's revenue is further bolstered by strategic collaborations and licensing agreements, enhancing market access while maintaining high-quality standards in their product offerings. Conform Pharm plans to leverage the recent Series B+ funding raised in May 2025 for new product development initiatives. The company aims to introduce upcoming products focused on pediatric and ophthalmic therapies, although specific release dates have not been disclosed.

In addition, Conform Pharm is strategizing to expand its market presence beyond its current operations, although targeted regions for expansion have not been specified. This strategic growth will be supported by the funding received from new investor Wuhan Optical Valley Financial Holding Group, along with returning investors THG Ventures and Sunz Fund.